PDS Biotechnology Corporation reports developments in targeted cancer immunotherapies based on its Versamune platform. Company news centers on PDS0101, also called Versamune HPV, in HPV16-positive head and neck cancer, and on PDS01ADC, an IL-12 fused antibody drug conjugate and tumor-targeted immunocytokine evaluated across multiple solid tumor indications.
Recurring updates include clinical-trial data, National Cancer Institute-led study presentations, FDA and IND protocol communications, scientific publications, patent coverage for core technology, quarterly financial results, and broader corporate-program updates.
PDS Biotechnology Corporation (Nasdaq: PDSB) reported a net loss of $0.6 million, or ($0.03) per share, for Q2 2021, a reduction from $2.9 million in Q2 2020, primarily due to $4.5 million from NJ tax benefit sales. Significant clinical results were highlighted, showing tumor reduction in 83% of HPV16-positive patients not previously treated with checkpoint inhibitors and 58% in those who had. The company completed a $52 million public offering to advance its pipeline and appointed new experts to its Scientific Advisory Board.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced presentations at various investor conferences in Q3 2021, highlighting interim data on its lead asset, PDS0101. At the ASCO 2021 Meeting, results showed tumor reduction in 83% of advanced cancer patients who failed prior treatments, and 58% in those who also failed checkpoint inhibitors. PDS0101 targets HPV16-positive cancers and is involved in ongoing Phase 2 studies. Upcoming conferences include BTIG on August 10, HC Wainwright on September 14, and Cantor on September 27.
PDS Biotechnology Corporation (Nasdaq: PDSB) will release its Q2 2021 financial results on August 12, 2021, before the market opens. Following the release, a conference call will be held at 8:00 am ET to review the results and provide a business update. PDS Biotech is focused on developing novel cancer therapies using its proprietary Versamune T-cell activating technology, with its lead product PDS0101 currently in three Phase 2 clinical studies targeting HPV-associated cancers. Interim results have shown strong efficacy in advanced, treatment-resistant cancers.
PDS Biotechnology Corporation (Nasdaq: PDSB) was added to the Russell Microcap® Index as of June 28, 2021. This inclusion enhances visibility among investors and confirms the company's progress in developing its lead HPV-cancer immunotherapy, PDS0101, currently in three Phase 2 trials. The Russell indexes, which benchmark approximately $10.6 trillion in assets, inform investment strategies globally. Dr. Frank Bedu-Addo emphasized that this recognition underscores the potential to improve cancer therapy effectiveness and increase shareholder value.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced the closing of its public offering of 6,088,235 shares at $8.50 each, raising approximately $51.7 million before expenses. The offering saw participation from insiders, including board members and executives. Cantor Fitzgerald & Co. managed the offering, which was made under a previously filed registration statement. PDS Biotech focuses on developing cancer immunotherapies using its proprietary Versamune® technology, with ongoing clinical studies for its lead product, PDS0101, in various cancers.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced a public offering of 5,294,118 shares at a price of $8.50 per share, aiming to raise approximately $45.0 million before expenses. The offering is expected to close around June 17, 2021, with Cantor Fitzgerald & Co. as the sole bookrunner. Proceeds will support the clinical pipeline development and general corporate needs. Additionally, underwriters can purchase an extra 794,117 shares within 30 days. This follows a previous shelf registration effective since July 31, 2020.
PDS Biotechnology Corporation (PDSB) announced an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The offering is subject to market conditions, with no guarantee on completion or specific terms. Proceeds from this offering will support the development of its clinical pipeline and general corporate purposes, including working capital. The registration statement for this offering was effective as of July 31, 2020, with preliminary prospectus materials filed with the SEC.
PDS Biotechnology Corporation (Nasdaq: PDSB) will host an Oncology R&D Day on June 16, 2021, at 8:00 am ET, aimed at analysts, investors, and the scientific community. The event will showcase advancements in the company's cancer immunotherapy pipeline utilizing the proprietary Versamune® technology. Key presentations will feature several experts, including company executives and researchers from the National Cancer Institute. A live webcast will be available, along with presentations published on the company’s website the following day.
Summary not available.
PDS Biotechnology Corporation announced interim data from its Phase 2 trial (NCT04287868) of PDS0101 (Versamune®-HPV16) at the ASCO 2021 Annual Meeting. The trial shows promising results: 83% tumor reduction in checkpoint inhibitor naïve patients and 58% in checkpoint inhibitor refractory patients. Among the 25 patients, 100% failed chemotherapy, 96% failed both chemotherapy and radiation, and 56% were checkpoint inhibitor refractory. Notably, the overall response rate compares favorably with current standards, highlighting PDS0101's potential for advanced HPV16-associated cancers.